Mehran Afshar1, Fawaz Al-Alloosh1, Sarah Pirrie2, Clare Rowan1, Nicholas D James3, Emilio Porfiri4. 1. Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K. 2. School of Cancer Sciences, University of Birmingham, Birmingham, U.K. 3. Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K. Cancer Research Centre, University of Warwick, Warwick, U.K. 4. Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K. e.porfiri@bham.ac.uk.
Abstract
BACKGROUND: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolving. Rationalisation of treatment requires identification of those patients more likely to benefit from a particular therapy. We reviewed the outcome of patients treated with abiraterone at our Institution to describe factors predictive for response. PATIENTS AND METHODS: Patients with CRCP treated with abiraterone were identified. Baseline variables and potential prognostic factors were extracted from electronic records. Outcome measures included overall survival (OS), prostate-specific antigen (PSA) response and time to PSA progression (TTPP). The Kaplan-Meier method and Cox proportional hazards model were used to analyze survival data. RESULTS: A total of 61 patients met the inclusion criteria. In multivariate analysis, three independent predictors of OS were identified: Duration of response to androgen deprivation therapy (ADT) (hazard ratio(HR)=0.95, p=0.006), performance status (HR=7.4, p=0.013), and baseline haemoglobin (HR=0.47, p≤0.001). CONCLUSION: This study has identified three factors predictive for response to abiraterone in CRPC. Duration of response to ADT has not been previously shown to be a predictive factor for patients with CRCP. We suggest that a prospective validation is required. Copyright
BACKGROUND: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolving. Rationalisation of treatment requires identification of those patients more likely to benefit from a particular therapy. We reviewed the outcome of patients treated with abiraterone at our Institution to describe factors predictive for response. PATIENTS AND METHODS: Patients with CRCP treated with abiraterone were identified. Baseline variables and potential prognostic factors were extracted from electronic records. Outcome measures included overall survival (OS), prostate-specific antigen (PSA) response and time to PSA progression (TTPP). The Kaplan-Meier method and Cox proportional hazards model were used to analyze survival data. RESULTS: A total of 61 patients met the inclusion criteria. In multivariate analysis, three independent predictors of OS were identified: Duration of response to androgen deprivation therapy (ADT) (hazard ratio(HR)=0.95, p=0.006), performance status (HR=7.4, p=0.013), and baseline haemoglobin (HR=0.47, p≤0.001). CONCLUSION: This study has identified three factors predictive for response to abiraterone in CRPC. Duration of response to ADT has not been previously shown to be a predictive factor for patients with CRCP. We suggest that a prospective validation is required. Copyright
Authors: Caroline S Clarke; Rachael M Hunter; Andrea Gabrio; Christopher D Brawley; Fiona C Ingleby; David P Dearnaley; David Matheson; Gerhardt Attard; Hannah L Rush; Rob J Jones; William Cross; Chris Parker; J Martin Russell; Robin Millman; Silke Gillessen; Zafar Malik; Jason F Lester; James Wylie; Noel W Clarke; Mahesh K B Parmar; Matthew R Sydes; Nicholas D James Journal: PLoS One Date: 2022-06-02 Impact factor: 3.752
Authors: Cecília M Alvim; André Mansinho; Rita S Paiva; Raquel Brás; Patrícia M Semedo; Soraia Lobo-Martins; Carolina B da Ponte; Daniela Macedo; Leonor Ribeiro; José P Dos Reis; Isabel Fernandes; Luís Costa Journal: Future Sci OA Date: 2019-12-12